Swiss National Bank increased its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 2.6% during the fourth quarter, Holdings Channel reports. The fund owned 63,800 shares of the company’s stock after acquiring an additional 1,600 shares during the quarter. Swiss National Bank’s holdings in Omnicell were worth $3,094,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Marco Investment Management LLC acquired a new stake in Omnicell during the third quarter worth approximately $231,000. Stevens Capital Management LP acquired a new stake in Omnicell during the third quarter worth approximately $305,000. Sei Investments Co. boosted its position in Omnicell by 76.7% during the third quarter. Sei Investments Co. now owns 8,219 shares of the company’s stock worth $420,000 after acquiring an additional 3,567 shares during the last quarter. Janney Capital Management LLC boosted its position in Omnicell by 45.3% during the third quarter. Janney Capital Management LLC now owns 9,484 shares of the company’s stock worth $484,000 after acquiring an additional 2,957 shares during the last quarter. Finally, Shelton Capital Management boosted its position in Omnicell by 17.6% during the fourth quarter. Shelton Capital Management now owns 9,800 shares of the company’s stock worth $475,000 after acquiring an additional 1,464 shares during the last quarter. Hedge funds and other institutional investors own 99.52% of the company’s stock.
In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total transaction of $99,554.94. Following the transaction, the chief financial officer now owns 40,544 shares of the company’s stock, valued at $2,095,719.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 3.77% of the company’s stock.
Omnicell, Inc. (NASDAQ:OMCL) opened at $44.75 on Wednesday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.28 and a current ratio of 1.73. The firm has a market cap of $1,702.58, a P/E ratio of 258.23, a price-to-earnings-growth ratio of 3.62 and a beta of 0.75. Omnicell, Inc. has a one year low of $36.65 and a one year high of $55.40.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.54 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.02. The company had revenue of $198.26 million for the quarter, compared to the consensus estimate of $205.50 million. Omnicell had a net margin of 2.88% and a return on equity of 1.54%. Omnicell’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.37 earnings per share. equities analysts expect that Omnicell, Inc. will post 0.77 EPS for the current year.
OMCL has been the topic of a number of analyst reports. Cantor Fitzgerald restated a “buy” rating and set a $60.00 target price on shares of Omnicell in a research report on Wednesday, December 13th. Oppenheimer restated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Tuesday, December 5th. Zacks Investment Research upgraded shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Craig Hallum downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Piper Jaffray Companies increased their price target on shares of Omnicell from $38.00 to $44.00 and gave the stock a “neutral” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $56.14.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).